Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: Synthesis, SAR, and in vivo assessment

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6489-6492

  Luci, Diane K ^a   Ghosh, Shyamali ^a   Smith, Charles E ^a   Qi, Jenson ^a   Wang, Yuanping ^a   Haertlein, Barbara ^a   Parry, Tom J ^a   Li, Jian ^a   Almond Jr , Harold R ^a   Minor, Lisa K ^a   Damiano, Bruce P ^a   Kinney, William A ^a   Maryanoff, Bruce E ^a   Lawson, Edward C ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antagonist; Ear flush; Piperidine; Urotensin

Indexed keywords

4 PHENYLPIPERIDINE BENZOXAZIN 3 ONE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN 2 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOXAZINES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; PIPERIDINES; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP; UROTENSINS;

RATTUS;

EID: 35648974717     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.092     Document Type: Article

References (24)

1. Pearson D., Shively J.E., Clark B.R., Geschwind I.I., Barkley M., Nishioka R.S., and Bern H.A. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 5021
2. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., Conlon J.M., Bern H.A., and Vaudry H. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 15803
3. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Cauermelch C.F., Coatney R.W., Zhaohui A., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W.P., Ohlstein E.H., Bergsma E.J., and Douglas S.A. Nature 401 (1999) 282
4. Elashourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J., Ao Z., Maleeff B., Naselsky D., Disa J., and Aiyar N.V. Br. J. Pharmacol. 136 (2002) 9
5. Flohr S., Kurz M., Kostenis E., Brkovich A., Fournier A., and Klabunde T. J. Med. Chem. 45 (2002) 1799
6. Kinney W.A., Almond Jr. H.R., Qi J., Smith C.E., Santulli R.J., de Garavilla L., Andrade-Gordon P., Cho D.S., Everson A.M., Feinstein M.A., Leung P.A., and Maryanoff B.E. Angew. Chem. Int. Ed. 41 (2002) 2940
7. Maguire J.J., Kuc R.E., and Davenport A.P. Br. J. Pharmacol. 131 (2000) 441
8. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Br. J. Pharmacol. 130 (2000) 1865
9. Zhang A.Y., Chen Y.F., Zhang C.X., Yi F.X., Qi J., Andrade-Gordon P., de Garavilla L., Li P.L., and Zou A.P. Am. J. Physiol. Renal Physiol. 285 (2003) F792
10. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., and Hirata Y. J. Hpertens. 19 (2001) 2185
11. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Lancet 359 (2002) 1990
12. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., Kimura Y., Sasano H., and Murakami O. Lancet 358 (2001) 810
13. Jin J., Dhanak D., Knight S.D., Widdowson K., Aiyar N., Naselsky D., Sarau H.M., Foley J.J., Schmidt D.B., Bennett C.D., Wang B., Warren G.L., Moore M.L., Keenan R.M., Rivero R.A., and Douglas S.A. Bioor. Med. Chem. Lett. 15 (2005) 3229
14. Douglas S.A., Behm D.J., Aiyar N.V., Naselsky D., Disa J., Brooks D.P., Ohlstein E.H., Gleason J.G., Sarau H.M., Foley J.J., Buckley P.T., Schmidt D.B., Wixted W.E., Widdowson K., Riley G., Jin J., Gallagher T.F., Schmidt S.J., Ridgers L., Christmann L.T., Keenan R.M., Knight S.D., and Dhanak D. Br. J. Pharmacol. 145 (2005) 620
15. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. J. Pharmacol. Exp. Ther. 316 (2006) 1115
16. Carotenuto A., Grieco P., Rovero P., and Novellino E. Curr. Med. Chem. 13 (2006) 267
17. 50s were calculated by using a log-logit plot of percent inhibition. See Ref. 2b for further details.
18. 4-Phenyl-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester was purchased from Arch Chemicals, Inc., and 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester was purchased from Chem-Impex International, Inc.
19. Eastwood P.R. Tetrahedron Lett. 41 (2000) 3705
20. i calculated via the Cheung-Prussoff equation. See Ref. 10 for further details.
21. Qi J.-S., Minor L.K., Smith C., Hu B., Yang J., Andrade-Gordon P., and Damiano B. Peptides 26 (2005) 683
22. 2H: C, 46.58; H, 4.63; N, 6.76. Found: C, 46.25, H, 4.48; N, 6.73.
23. An optimized rat U-II homology model was constructed by using bovine rhodopsin X-ray crystal structure (PDB code 1L9H) as a template and following the same procedure described in Ref. 2b Molecular docking into the homology model was done using Glide (Schrodinger LLC, Portland, OR) with OPLS_2005 force field. Feature constraint was employed in docking, using Asp-130 as an anchor point. A basic nitrogen feature has to be fitted into the proximity of the carboxylic acid oxygen atoms.
24. Qi J., Schulingkamp R., Parry T.J., Colburn R., Stone D., Haertlein B., Minor L.K., Andrade-Gordon P., and Damiano B.P. Br. J. Pharmcol. 150 (2007) 415